Reata Pharmaceuticals, Inc.

127 articles with Reata Pharmaceuticals, Inc.

• Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia

  11/18/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich’s ataxia.

• Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

  11/8/2021

  Reata Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2021, and provided an update on the Company’s business operations and clinical development programs.

• Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021

  11/1/2021

  Reata Pharmaceuticals, Inc. today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on November 8, 2021.

• Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome

  10/28/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its submission of a Marketing Authorization Application (“MAA”) for bardoxolone methyl (“bardoxolone”) to the European Medicines Agency (“EMA”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

• Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

  9/30/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has completed its pre-New Drug Application meeting with the United States Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich’s ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022.

• 

  Texas Plants its Flag as Next US Biotech Hub

  9/2/2021

  BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it's now accepting applications. 

• Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

  8/9/2021

  Reata Pharmaceuticals, Inc. today announced financial results for the quarter ended June 30, 2021, and provided an update on the Company’s business operations and clinical development programs.

• Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021

  8/2/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will report financial results and provide an update on recent progress on its development programs after the market closes on August 9, 2021.

• Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference

  6/7/2021

  Reata Pharmaceuticals, Inc. today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference

• Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia

  5/19/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”)

• Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

  5/6/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended March 31, 2021, and provided an update on the Company’s business operations and clinical development programs.

• Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - May 03, 2021

  5/3/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that management will present and hold 1x1 meetings at the following investor conferences

• Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021

  4/28/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on May 6, 2021.

• Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome

  4/26/2021

  Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies Application Assigned a P DUFA Date of February 25, 2022

• Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors

  4/15/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.

• Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences

  3/29/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) will be presented at two upcoming nephrology conferences including The World Congress of Nephrology 2021 being held virtually from April 15 – 19, 2021 and the 58th European Renal Association and European Dialysis

• Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome

  3/1/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has submitted a New Drug Application for bardoxolone methyl for the treatment of chronic kidney disease caused by Alport syndrome to the U.S. Food and Drug Administration.

• Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs

  3/1/2021

  Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter and full year ended December 31, 2020, and provided an update on the Company’s business operations and clinical development programs.

• Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021

  2/22/2021

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on March 1, 2021.

• Reata Pharmaceuticals. Announces Closing of Class A Common Stock Offering

  12/4/2020

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Cla